MB 102

Drug Profile

MB 102

Alternative Names: Anti-CD123 chimeric antigen receptor T cell therapy - Mustang Bio; MB 102 - Mustang Bio; MB102

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 08 Dec 2017 Efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia presented at 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem- 2017)
  • 01 Oct 2017 UMass Medicine Science Park and Mustang bio entered into an agreement to support the clinical development and commercialisation of CAR T therapies
  • 01 Feb 2017 Mustang Bio entered into three amended and restated exclusive patent license agreements for MB 102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top